信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

国庆日翌日休市 09-29 16:08:22

38.250

-1.650

-4.14%

最高39.900	最低38.150	成交量309.95万
今开39.900	昨收39.900	日振幅4.39%
总市值615.98亿	流通市值615.98亿	总股本16.10亿
成交额1.19亿	换手率0.19%	流通股本16.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":38.25,"timestamp":1695974902027,"preClose":39.9,"halted":0,"volume":3099480,"delay":0,"floatShares":1610392916,"shares":1610392916,"eps":-1.5689391,"marketStatus":"国庆日翌日休市","marketStatusCode":7,"change":-1.65,"latestTime":"09-29 16:08:22","open":39.9,"high":39.9,"low":38.15,"amount":119377477,"amplitude":0.04386,"askPrice":38.35,"askSize":2000,"bidPrice":38.25,"bidSize":64000,"shortable":3,"etf":0,"ttmEps":-0.9621471824846676,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1696296600000},"adr":0,"listingDate":1540915200000,"adjPreClose":39.9,"volumeRatio":0.25490798284992666,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2372008329","title":"智通港股通占比异动统计|10月2日","url":"https://stock-news.laohu8.com/highlight/detail?id=2372008329","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2372008329?lang=zh_cn&edition=full","pubTime":"2023-10-02 08:35","pubTimestamp":1696206941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据2023年9月27日披露数据，马可数字科技、普达特科技、友联国际教育租赁港股通持股占比增加值最大，分别增加1.06%、0.46%、0.43%；恒生中国企业、南方恒生科技、盈富基金港股通持股占比减少值最大，分别减少-2.48%、-2.40%、-1.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1002019.html","is_publish_highlight":false},{"id":"2371596920","title":"智通港股空仓持单统计|9月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2371596920","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2371596920?lang=zh_cn&edition=full","pubTime":"2023-09-29 18:30","pubTimestamp":1695983404,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止9月22日，未平仓空单比位列前三位为药明康德、福莱特玻璃、中国中免，空仓比分别为20.19%、18.79%、15.61%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1001870.html","is_publish_highlight":false},{"id":"2371037452","title":"港股异动 | 信达生物(01801)现跌超4% 公司主动撤回帕萨利司片的新药上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2371037452","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2371037452?lang=zh_cn&edition=full","pubTime":"2023-09-29 15:10","pubTimestamp":1695971400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物现跌超4%，截至发稿，跌3.76%，报38.4港元，成交额7576.47万港元。消息面上，信达生物公布，此前，该公司向中国国家药品监督管理局递交了帕萨利司片的新药上市许可申请，用于治疗既往接受过至少两种系统性治疗的复发或难治性滤泡性淋巴瘤的成人患者，并于2023年1月获受理。公司基于整体研发策略和产品价值管理的考量，决定主动撤回帕萨利司片的该项申请，并将资源集中投入在更多重要管线上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1001748.html","is_publish_highlight":false},{"id":"2371082113","title":"智通港股通占比异动统计|9月29日","url":"https://stock-news.laohu8.com/highlight/detail?id=2371082113","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2371082113?lang=zh_cn&edition=full","pubTime":"2023-09-29 08:35","pubTimestamp":1695947742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据2023年9月28日披露数据，马可数字科技、普达特科技、友联国际教育租赁港股通持股占比增加值最大，分别增加1.06%、0.46%、0.43%；恒生中国企业、南方恒生科技、盈富基金港股通持股占比减少值最大，分别减少-2.48%、-2.40%、-1.25%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1001685.html","is_publish_highlight":false},{"id":"2371082341","title":"完全缓解率82.4%！信达生物与驯鹿生物宣布在2023年国际骨髓瘤学会（IMS）年会壁报展示BCMA CAR-T福可苏®（伊基奥仑赛注射液）的长期随访数据更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2371082341","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2371082341?lang=zh_cn&edition=full","pubTime":"2023-09-29 08:00","pubTimestamp":1695945600,"startTime":"0","endTime":"0","summary":"所有受试者的CRS和ICANS均得到缓解。伊基奥仑赛注射液为全人源靶向BCMA CAR-T产品，能够更为精准地杀伤肿瘤细胞，且体内存续更持久。目前，同时还有7个新药分子进入III期或关键性临床研究，另外还有17个新药品种已进入临床研究。至2023年3月，信达生物患者援助项目已惠及16余万普通患者，药物捐赠总价值数亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4221672_ZH21672_1","is_publish_highlight":false},{"id":"2370248877","title":"信达生物(01801)决定主动撤回帕萨利司片的新药上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2370248877","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2370248877?lang=zh_cn&edition=full","pubTime":"2023-09-28 16:35","pubTimestamp":1695890156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，此前，该公司向中国国家药品监督管理局递交了帕萨利司片的新药上市许可申请，用于治疗既往接受过至少两种系统性治疗的复发或难治性滤泡性淋巴瘤的成人患者，并于2023年1月获受理。该公司基于整体研发策略和产品价值管理的考量，决定主动撤回帕萨利司片的本项申请，并将资源集中投入在更多重要管线上，一如既往地坚持高质量的产品开发，满足更多未被满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230928163804840bd209&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230928163804840bd209&s=b","is_publish_highlight":false},{"id":"2370748729","title":"信达生物9月27日获南向资金加仓349.60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2370748729","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370748729?lang=zh_cn&edition=full","pubTime":"2023-09-28 09:31","pubTimestamp":1695864663,"startTime":"0","endTime":"0","summary":"9月27日, 南向资金增持信达生物349.60万股。截止当日收盘，港股通共持有信达生物39155.41万股，占流通股24.31%。信达生物近5个交易日上涨6.38%，港股通累计增持882.34万股；近20个交易日上涨13.63%，港股通累计增持6934.51万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230928094029840aad2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230928094029840aad2c&s=b","is_publish_highlight":false},{"id":"2370874813","title":"南向资金9月27日净卖出汇丰控股114.32万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2370874813","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370874813?lang=zh_cn&edition=full","pubTime":"2023-09-28 09:30","pubTimestamp":1695864659,"startTime":"0","endTime":"0","summary":"9月27日，南向资金减持汇丰控股114.32万股连续7日减持。截止当日收盘，港股通共持有汇丰控股181044.65万股，占流通股9.09%。港股通减持金额前五个股分别为中国移动、中国海洋石油、腾讯控股、香港交易所、汇丰控股。汇丰控股近5个交易日下跌0.41%，港股通累计减持558.92万股；近20个交易日上涨2.53%，港股通累计减持454.97万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023092809394582705047&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023092809394582705047&s=b","is_publish_highlight":false},{"id":"2370371406","title":"智通港股通占比异动统计|9月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2370371406","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370371406?lang=zh_cn&edition=full","pubTime":"2023-09-28 08:35","pubTimestamp":1695861348,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据2023年9月27日披露数据，恒生中国企业、南方恒生科技、盈富基金港股通持股占比增加值最大，分别增加2.54%、1.71%、1.28%；齐合环保、中国奥园、JS环球生活港股通持股占比减少值最大，分别减少-2.97%、-1.85%、-0.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000968.html","is_publish_highlight":false},{"id":"2370711339","title":"智通港股通资金流向统计(T+2)|9月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2370711339","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370711339?lang=zh_cn&edition=full","pubTime":"2023-09-28 07:30","pubTimestamp":1695857458,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，9月25日,盈富基金、恒生中国企业、南方恒生科技南向资金净流入金额位列市场前三，分别净流入16.71 亿、7.77 亿、6.21 亿中国移动、中国海洋石油、腾讯控股南向资金净流出金额位列市场前三，分别净流出-5.28 亿、-3.13 亿、-2.16 亿在净流入比方面，中船防务、青岛银行、渤海银行以85.69%、84.87%、81.62%位列市场前三。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000939.html","is_publish_highlight":false},{"id":"2370695797","title":"智通港股解盘 | 节前平稳过度为主 减肥药持续爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2370695797","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370695797?lang=zh_cn&edition=full","pubTime":"2023-09-27 19:44","pubTimestamp":1695815044,"startTime":"0","endTime":"0","summary":"监管层也在积极行动，9月26日晚间，沪深交易所分别发布关于进一步规范股份减持行为有关事项的通知，并明确即日实施。这一数据大幅超过市场预期。减肥药需求暴增，多肽类生产需求水涨船高。两只品种涨幅均在6个点以上。对于接下来恒指的走势，整体预计偏向平稳过度。此外，欧佩克再次延长减产消息利好油价，供需局面又进一步收紧。另外，在8月底，公司赛沃替尼在中国获纳入突破性治疗品种用于治疗胃癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000813.html","is_publish_highlight":false},{"id":"2370376309","title":"智通港股通活跃成交|9月27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2370376309","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370376309?lang=zh_cn&edition=full","pubTime":"2023-09-27 19:00","pubTimestamp":1695812401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2023年9月27日当天，美团-W、中国海洋石油、腾讯控股位居沪港通（南向）成交额前3位，成交额分别为6.90 亿元、5.41 亿元、5.19 亿元；美团-W、腾讯控股、药明生物 位居深港通（南向）成交额前3位，成交额分别为8.06 亿元、4.69 亿元、3.82 亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000760.html","is_publish_highlight":false},{"id":"2370421750","title":"突发腰斩...","url":"https://stock-news.laohu8.com/highlight/detail?id=2370421750","media":"中国基金报","top":-1,"share":"https://www.laohu8.com/m/news/2370421750?lang=zh_cn&edition=full","pubTime":"2023-09-27 17:40","pubTimestamp":1695807600,"startTime":"0","endTime":"0","summary":"举报无效 复牌腰斩停牌近6个月的旭辉控股集团复牌大跌58%。复牌时补充披露的2022年财报显示，公司实现营业总收入475.6亿元人民币，同比下滑56%；股东权益应占净亏损约为130.5亿元人民币，2021年同期公司盈利76.1亿元人民币。今年上半年，公司收入规模同比出现小幅上升，同比增长5%达313.3亿元人民币，上半年亏损89.7亿元人民币，2022年同期为盈利7.3亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2655959026&idx=2&sn=a1852da354c8bf2b8834e492a859b35d&chksm=8baa5dcdbcddd4db872a56cc0c314850a60b6aee640d4652688d2478a80ade85a5890a2aa2ce&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2655959026&idx=2&sn=a1852da354c8bf2b8834e492a859b35d&chksm=8baa5dcdbcddd4db872a56cc0c314850a60b6aee640d4652688d2478a80ade85a5890a2aa2ce&scene=0#rd","is_publish_highlight":false},{"id":"2370756524","title":"大行评级｜大和：中资医药股首选药明康德、药明生物及信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2370756524","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2370756524?lang=zh_cn&edition=full","pubTime":"2023-09-27 15:55","pubTimestamp":1695801315,"startTime":"0","endTime":"0","summary":"该行看好药明康德近期增长能见度高，目标价102港元；预期药明生物今年下半年及明年各方面都会逐步改善，包括项目收益、产能利用率和毛利率，目标价73.3港元；视信达生物为投资内地生物科技的替代标的，其商品组合快速增长，目标价50港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927155702826e32c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927155702826e32c2&s=b","is_publish_highlight":false},{"id":"2370730653","title":"港股医药板块表现强势，信达生物涨超8%，港股医药ETF(159718)上涨2.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370730653","media":"有连云","top":-1,"share":"https://www.laohu8.com/m/news/2370730653?lang=zh_cn&edition=full","pubTime":"2023-09-27 14:10","pubTimestamp":1695795023,"startTime":"0","endTime":"0","summary":"截至2023年9月27日 13:51，中证港股通医药卫生综合指数强势上涨2.89%，成分股信达生物上涨8.38%，药明康德上涨7.84%，泰格医药上涨7.24%，康龙化成，和黄医药等个股跟涨。港股医药ETF上涨2.39%，最新价报0.73元，换手率8.41%。港股医药ETF持续溢价交易，截至发布溢折率0.44%。值得注意的是，该基金跟踪的中证港股通医药卫生综合指数估值处于历史低位，最新市净率PB为1.98倍，低于指数近1年85.94%以上的时间，估值性价比突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://finance.ifeng.com/c/8TQ8WH2RVkb","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8TQ8WH2RVkb","is_publish_highlight":false},{"id":"2370734158","title":"信达生物午盘涨幅持续扩大 股价现涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370734158","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2370734158?lang=zh_cn&edition=full","pubTime":"2023-09-27 13:25","pubTimestamp":1695792300,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　信达生物（01801）午盘涨幅持续扩大，上涨8.51%，现报41.45港元，成交额4.87亿港元。\n　　东吴证券近日研报指出，随着肥胖人群的增加、居民体重管理和健康意识的增强，减肥需求市场将持续增长。诺和诺德GLP-1类药物在国际市场的市占率（按收入算）则稳步上升。信达生物的玛仕度肽（GLP1/GCGR）是国产进度最快的GLP1双靶药，减重效果优异，先发优势明显。重点关注信达生物。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-27/doc-imzpcmzr4253359.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2023-09-27/doc-imzpcmzr4253359.shtml","is_publish_highlight":false},{"id":"2370573679","title":"港股异动 | 信达生物(01801)涨超7%创4个月新高 玛仕度肽为国产进度最快的GLP1双靶药","url":"https://stock-news.laohu8.com/highlight/detail?id=2370573679","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370573679?lang=zh_cn&edition=full","pubTime":"2023-09-27 11:44","pubTimestamp":1695786259,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物涨超7%，触及41.1港元创4个月新高。截至发稿，涨7.46%，报41.05港元，成交额3.77亿港元。信达生物的玛仕度肽是国产进度最快的GLP1双靶药，减重效果优异，先发优势明显。重点关注信达生物。信达生物此前宣布，配股募资约23.57亿港元用于加速多项临床研发计划及产品商业化。本次融资中约30%将用于开发、营销及商业化IBI362，一种治疗糖尿病及肥胖的GLP-1R/GCGR双激动剂及潜在临床阶段最佳候选药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000391.html","is_publish_highlight":false},{"id":"2370780467","title":"信达生物盘中异动 股价大涨5.10%报40.151港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2370780467","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370780467?lang=zh_cn&edition=full","pubTime":"2023-09-27 09:54","pubTimestamp":1695779682,"startTime":"0","endTime":"0","summary":"2023年09月27日早盘09时54分，信达生物股票出现波动，股价大幅上涨5.10%。截至发稿，该股报40.151港元/股，成交量212.4万股，换手率0.13%，振幅6.54%。资金方面，该股资金流入4946.97万港元，流出1772.19万港元。信达生物股票所在的药品行业中，整体涨幅为0.25%。其相关个股中，泰凌医药、联邦制药、信达生物涨幅较大，振幅较大的相关个股有华控康泰、联邦制药、信达生物，振幅分别为7.50%、6.94%、6.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927095443838efb49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927095443838efb49&s=b","is_publish_highlight":false},{"id":"2370127884","title":"股价逆大盘上涨逾34%！信达生物是否见底？","url":"https://stock-news.laohu8.com/highlight/detail?id=2370127884","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2370127884?lang=zh_cn&edition=full","pubTime":"2023-09-26 19:01","pubTimestamp":1695726083,"startTime":"0","endTime":"0","summary":"在过去的两年多时间里，和百济神州（06160.HK）、君实生物（01877.HK）等生物科技企业一样，信达生物（01801.HK）的股价亦遭遇了持续的下跌。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202309_1/c06cdcce-993e-4de1-bf4f-99e2abeca8e1.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202309_1/c06cdcce-993e-4de1-bf4f-99e2abeca8e1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/6512ba03bde0b375aabeace7","is_publish_highlight":false},{"id":"2370251351","title":"信达生物盘中异动 大幅上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370251351","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370251351?lang=zh_cn&edition=full","pubTime":"2023-09-25 15:50","pubTimestamp":1695628214,"startTime":"0","endTime":"0","summary":"2023年09月25日临近收盘15时50分，信达生物股票出现异动，股价急速拉升5.07%。截至发稿，该股报39.351港元/股，成交量1203.24万股，换手率0.75%，振幅6.14%。信达生物股票所在的药品行业中，整体跌幅为0.04%。其相关个股中，泰凌医药、信达生物、联康生物科技集团涨幅较大，振幅较大的相关个股有泰凌医药、衍生集团、中生联合，振幅分别为25.32%、13.16%、10.21%。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230925155015838e711b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230925155015838e711b&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":0.064},{"period":"3month","weight":0.2922},{"period":"6month","weight":0.0882},{"period":"1year","weight":0.53},{"period":"ytd","weight":0.1418}],"websiteUrl":"http://www.innoventbio.com","compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0364},{"period":"3month","weight":-0.0585},{"period":"6month","weight":-0.127},{"period":"1year","weight":0.0375},{"period":"ytd","weight":-0.0997}],"name":"信达生物","description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.006413},{"month":2,"riseRate":0.6,"avgChangeRate":0.053308},{"month":3,"riseRate":0.2,"avgChangeRate":-0.038922},{"month":4,"riseRate":0.6,"avgChangeRate":0.023538},{"month":5,"riseRate":0.4,"avgChangeRate":0.023793},{"month":6,"riseRate":0.6,"avgChangeRate":0.132633},{"month":7,"riseRate":0.2,"avgChangeRate":-0.046248},{"month":8,"riseRate":0.8,"avgChangeRate":-0.016733},{"month":9,"riseRate":0.6,"avgChangeRate":0.024076},{"month":10,"riseRate":0.25,"avgChangeRate":0.003987},{"month":11,"riseRate":0.6,"avgChangeRate":0.083332},{"month":12,"riseRate":0.6,"avgChangeRate":0.099815}],"exchange":"SEHK","nameEN":"INNOVENT BIO","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.17.2","shortVersion":"4.17.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}